GYRE
Gyre Therapeutics Inc.Key Statistics
About Gyre Therapeutics Inc.
Gyre Therapeutics Inc. is a cutting-edge biopharmaceutical company dedicated to developing innovative therapies for rare and complex diseases. By utilizing a proprietary platform, Gyre accelerates the discovery and commercialization of precision treatments aimed at addressing significant unmet medical needs. The company's strong focus on scientific excellence and patient-centered outcomes, coupled with its advancing pipeline in gene therapy and precision medicine, positions Gyre for substantial growth within the competitive biopharmaceutical landscape. Through strategic partnerships and a commitment to research, Gyre is poised to make a meaningful impact on the lives of patients facing challenging health conditions.
Fundamentals
| Revenue (TTM) | $116.59M |
| Gross Profit (TTM) | $111.17M |
| EBITDA | $14.01M |
| Operating Margin | 0.32% |
| Return on Equity | 8.21% |
| Return on Assets | 4.93% |
| Revenue/Share (TTM) | $1.30 |
| Book Value | $1.16 |
| Price-to-Book | 7.14 |
| Price-to-Sales (TTM) | 6.59 |
| EV/Revenue | 6.05 |
| EV/EBITDA | 50.32 |
| Quarterly Earnings Growth (YoY) | 166.20% |
| Quarterly Revenue Growth (YoY) | 33.40% |
| Shares Outstanding | $96.99M |
| Float | $20.95M |
| % Insiders | 81.60% |
| % Institutions | 3.48% |
Historical Volatility
Volatility is currently expanding